Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1962 1
1963 4
1964 3
1965 2
1966 5
1967 5
1968 6
1969 6
1970 4
1971 2
1972 6
1973 4
1975 1
1976 3
1977 1
1978 1
1979 1
1980 2
1981 4
1982 2
1983 3
1984 3
1985 6
1986 4
1987 9
1988 4
1989 10
1990 6
1991 8
1992 9
1993 14
1994 11
1995 10
1996 11
1997 11
1998 11
1999 17
2000 18
2001 16
2002 12
2003 11
2004 11
2005 10
2006 3
2007 6
2008 12
2009 11
2010 22
2011 15
2012 18
2013 14
2014 16
2015 12
2016 8
2017 12
2018 10
2019 18
2020 13
2021 20
2022 19
2023 17
2024 15
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

512 results

Results by year

Filters applied: . Clear all
Page 1
Relapsed and refractory multiple myeloma: A systematic review and network meta-analysis of the efficacy of novel therapies.
Minakata D, Fujiwara SI, Yokoyama D, Noguchi A, Aoe S, Oyama T, Koyama S, Murahashi R, Nakashima H, Hyodo K, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Nagayama T, Mashima K, Umino K, Morita K, Ashizawa M, Yamamoto C, Hatano K, Sato K, Ohmine K, Kanda Y. Minakata D, et al. Among authors: nagayama t. Br J Haematol. 2023 Mar;200(6):694-703. doi: 10.1111/bjh.18654. Epub 2023 Jan 20. Br J Haematol. 2023. PMID: 36661264 Review.
Cost-Effectiveness of Anti-BCMA Chimeric Antigen Receptor T Cell Therapy in Relapsed/Refractory Multiple Myeloma.
Yamamoto C, Minakata D, Yokoyama D, Furuki S, Noguchi A, Koyama S, Oyama T, Murahashi R, Nakashima H, Ikeda T, Kawaguchi SI, Hyodo K, Toda Y, Ito S, Nagayama T, Umino K, Morita K, Ashizawa M, Ueda M, Hatano K, Sato K, Ohmine K, Fujiwara SI, Kanda Y. Yamamoto C, et al. Among authors: nagayama t. Transplant Cell Ther. 2024 Jan;30(1):118.e1-118.e15. doi: 10.1016/j.jtct.2023.10.001. Epub 2023 Oct 5. Transplant Cell Ther. 2024. PMID: 37802181 Free article.
The data-driven future of high-energy-density physics.
Hatfield PW, Gaffney JA, Anderson GJ, Ali S, Antonelli L, Başeğmez du Pree S, Citrin J, Fajardo M, Knapp P, Kettle B, Kustowski B, MacDonald MJ, Mariscal D, Martin ME, Nagayama T, Palmer CAJ, Peterson JL, Rose S, Ruby JJ, Shneider C, Streeter MJV, Trickey W, Williams B. Hatfield PW, et al. Among authors: nagayama t. Nature. 2021 May;593(7859):351-361. doi: 10.1038/s41586-021-03382-w. Epub 2021 May 19. Nature. 2021. PMID: 34012079 Review.
Pathophysiology of pulmonary aspergillosis.
Shibuya K, Ando T, Hasegawa C, Wakayama M, Hamatani S, Hatori T, Nagayama T, Nonaka H. Shibuya K, et al. Among authors: nagayama t. J Infect Chemother. 2004 Jun;10(3):138-45. doi: 10.1007/s10156-004-0315-5. J Infect Chemother. 2004. PMID: 15290452 Review.
Risk factors for high-dose methotrexate-induced nephrotoxicity.
Kawaguchi S, Fujiwara SI, Murahashi R, Nakashima H, Matsuoka S, Ikeda T, Toda Y, Ito S, Ban T, Nagayama T, Umino K, Minakata D, Nakano H, Yamasaki R, Ashizawa M, Yamamoto C, Hatano K, Sato K, Oh I, Ohmine K, Kanda Y. Kawaguchi S, et al. Among authors: nagayama t. Int J Hematol. 2021 Jul;114(1):79-84. doi: 10.1007/s12185-021-03132-8. Epub 2021 Mar 20. Int J Hematol. 2021. PMID: 33743109
Dimethyl fumarate ameliorates graft-versus-host disease by inhibiting T-cell metabolism and immune responses through a reactive oxygen species-dependent mechanism.
Mashima K, Sato K, Ikeda T, Izawa J, Takayama N, Hayakawa H, Kawaguchi SI, Nakano H, Nagayama T, Umino K, Morita K, Tominaga K, Endo H, Kanda Y. Mashima K, et al. Among authors: nagayama t. Br J Haematol. 2022 Jun;197(6):e78-e82. doi: 10.1111/bjh.18082. Epub 2022 Feb 15. Br J Haematol. 2022. PMID: 35170051 No abstract available.
Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myeloma.
Yamamoto C, Minakata D, Koyama S, Sekiguchi K, Fukui Y, Murahashi R, Nakashima H, Matsuoka S, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Nagayama T, Umino K, Nakano H, Morita K, Yamasaki R, Ashizawa M, Ueda M, Hatano K, Sato K, Ohmine K, Fujiwara SI, Kanda Y. Yamamoto C, et al. Among authors: nagayama t. Blood. 2022 Aug 11;140(6):594-607. doi: 10.1182/blood.2021015220. Blood. 2022. PMID: 35580269 Free PMC article.
Antibody-mediated pathogenesis of chronic GVHD through DBY/HLA class II complexes and induction of a GVL effect.
Umino K, Morita K, Ikeda T, Kawaguchi SI, Nagayama T, Ito S, Minakata D, Ashizawa M, Yamamoto C, Hatano K, Sato K, Ohmine K, Fujiwara SI, Kimura SI, Kako S, Doki N, Ozawa Y, Mori Y, Eto T, Hiramoto N, Nakamae H, Kanda J, Ichinohe T, Atsuta Y, Nakasone H, Morishima S, Kanda Y. Umino K, et al. Among authors: nagayama t. Blood. 2023 Sep 14;142(11):1008-1021. doi: 10.1182/blood.2023019799. Blood. 2023. PMID: 37363859 Free article.
512 results